Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Expenses incurred under agreements		$ 1,241	$ 1,173	$ 2,404	$ 2,447
Interest expense	[1]	4,813	3,494	9,013	6,999
Sumitomo Pharma, Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan
Interest expense		$ 4,813	$ 2,885	$ 8,445	$ 5,789

[1] Includes $4,813 and $8,445 of interest expense under the Sumitomo Pharma Loan Agreement for the three and six months ended September 30, 2022, respectively. Includes $2,885 and $5,789 of interest expense under the Sumitomo Pharma Loan Agreement for the three and six months ended September 30, 2021, respectively. See Note 5(C).